NCT01402713View on ClinicalTrials.gov

To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

311

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Bacterial Infections
Interventions
BIOLOGICAL

GC1107

GC1107-T5.0: low dose, GC1107-T7.5: high dose

BIOLOGICAL

TD_PUR INJ / SK Td vaccine

step 1(phase 2)-TD\_PUR INJ step 2(phase 3)-SK Td vaccine

Trial Locations (1)

Unknown

The catholic university of Korea, Seoul st. mary's hospital, Banpo-dong

Sponsors
All Listed Sponsors
lead

Green Cross Corporation

INDUSTRY

NCT01402713 - To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children | Biotech Hunter | Biotech Hunter